The human T-lymphotropic virus type-I (HTLV-I)I4 has been identified as the cause of adult T-cell leukemia (ATL), an agressive, usually fatal T-cell ma1ignan~y.I~ Recently, a severe, slowly progressive myelopathy (tropical spastic paraparesis [TSP]) that is endemic in certain Cambean islands has also been associated with HTLV-I infection.I6 An identical disease has been reported to occur in HTLV-I-infected individuals in Japan and has been termed HTLV-I-associated myelopathy (HAM)." Autonomously growing, HTLV-I-infected T-cell lines can be established from the peripheral blood of ATLI8 and from the cerebrospinal fluid (CSF) of TSP/ HAM patients. '9,20 Similarily, continuously growing cell lines can be established by in vitro infection of T lymphocytes with HTLV-1.2' We recently reported that HTLV-I-infected T-cell lines constitutively express high levels of LT messenger RNA (mRNA) and release biologically active LT." Expression of HTLV-I structural proteins is not required for the activation of the LT gene in these cells2' and we postulated that an HTLV-I regulatory gene product, most likely tax, is involved in the activation of the LT gene. In the present report, we analyze the 5' untranslated region of the human LT gene and demonstrate that HTLV-I tax is indeed able to induce the expression of the human LT promoter.
L B lymphocytes after stimulation by antigen,' phytohemagglutinin (PHA),2,3 or phorbol myristate acetate (PMA).3.4 Besides the initially described cytotoxic effect of LT on a variety of cell lines in vitro5x6 and the induction of tumor necrosis of methylcholanthrene-induced sarcomas in vivo,' a variety of other biologic effects, such as the induction of surface antigen expression in various cell^,^.^ antiviral activity,"," the activation of osteoclasts, and the induction of bone re~orption,l'~~~ have been assigned to this lymphokine.
The human T-lymphotropic virus type-I (HTLV-I)I4 has been identified as the cause of adult T-cell leukemia (ATL), an agressive, usually fatal T-cell ma1ignan~y.I~ Recently, a severe, slowly progressive myelopathy (tropical spastic paraparesis [TSP] ) that is endemic in certain Cambean islands has also been associated with HTLV-I infection.I6 An identical disease has been reported to occur in HTLV-I-infected individuals in Japan and has been termed HTLV-I-associated myelopathy (HAM)." Autonomously growing, HTLV-I-infected T-cell lines can be established from the peripheral blood of ATLI8 and from the cerebrospinal fluid (CSF) of TSP/ HAM patients. '9,20 Similarily, continuously growing cell lines can be established by in vitro infection of T lymphocytes with HTLV-1.2 ' We recently reported that HTLV-I-infected T-cell lines constitutively express high levels of LT messenger RNA (mRNA) and release biologically active LT." Expression of HTLV-I structural proteins is not required for the activation of the LT gene in these cells2' and we postulated that an HTLV-I regulatory gene product, most likely tax, is involved in the activation of the LT gene. In the present report, we analyze the 5' untranslated region of the human LT gene and demonstrate that HTLV-I tax is indeed able to induce the expression of the human LT promoter.
MATERIALS AND METHODS
Cell lines. The human T-cell lines Jurkat (a gift of W. Greene, Howard Hughes Medical Institute, Department of Medicine, Duke University Medical Center, Durham, NC), the HTLV-I-infected Tcell line MT-2,18 and the monocytoid cell line U937 were maintained in RPMI-1640 medium containing 10% fetal calf serum plus 100 U/ mL penicillin and 100 pg/mL streptomycin at 37°C and 5% C02. 
Construction of the LT/choramphenicol acetyl transferase (CA r )
constructs. The 5' flanking region of the human LT gene (-819 to +I37 with respect to the CAP site) was obtained from a genomic cosmid clone (a gift of T. Spies, Department of Biochemistry and Molecular Biology, Cambridge, MA) cloned into the EcoRI and BamHI sites of the pSP72 plasmid (Promega, Madison, WI) and sequenced by the method of Sanger et alF3 Preexisting restriction enzyme sites ( Fig IC) were used to generate 5' deletion fragments, which were blunt-end ligated either into the BgI I1 site ofthe pCAT3M plasmid24 (Fig 1A) or into the Sal I site of a newly generated CAT plasmid that contains the Bgl I1 to BamHI CAT cassette of pCAT3M cloned into the BamHI site of the pSP72 plasmid (pspCAT2 ; Fig  1 B) . To generate the fragment -1 16/+ 137 of the LT gene, we used the polymerase chain reaction (PCR) technique using the original pSP72/LT plasmid as template. The 5' primer (5'-AAACAGCTGT-ATCTTCTAAGCCCTGGGGGCTTCCCCGG-3' ) introduced a Pvu 11 restriction enzyme (underlined) site at position -1 16, and the 3' inverse primer was situated in the polylinker of the pSP72 plasmid (5'-CCGGGTACCGAGCTCGMTTCATC-3' ). The DNA fragment resulting from amplification was digested with Pvu I1 and EcoRI, filled in with T4 DNA polymerase, and cloned into the blunt-ended Sal I site of the pSPCAT plasmid. For the mutation of the KB site by PCR, the 5' primer contained in addition the desired nucleotide changes (5'-AAACAGCTGTATCTTCTAAGCCCTt&tGGCTTCC-CCGG-3'). The LT gene has four possible initiation sites of tran~c r i p t i o n .~~ For present purposes, we arbitrarily used nucleotide position 8 18 of the genomic sequence published by Nedwin et aiz5 as the reference site for the initiation of transcription. fragments (position +137). The Pvu II* and Pvu II m u P fragments were generated by PCR using mutagenic primers as described in Materials and Methods.
From the Division
Other plasmids. The tax expression plasmid (pcTax) contains a full-length cDNA copy of the HTLV-I tax gene under the control of the human cytomegalovirus (CMV) immediate early promoter.26 The KS-M13+ or the pCEM4 plasmids were used as control DNA in several transfection protocols. The HTLV-I long terminal repeat (LTR)/CAT plasmid (HTLV-I LTR/CAT) consists of the LTR of the HTLV-I/CR isolate cloned 5' to the CAT gene resident in pSVOCAT.'' For DNA transfection, the diethyl aminoethyl (DEAE) dextran/cloroquine method was used. Cells (5 X lo6) were transfected as described by Holbrook et a1.28
MT-2 cells were transfected with 3 pg of DNA U937 and Jurkat cells were transfected with 6 pg of DNA per 5 X IO6 cells. In the latter case, 3 pg of the different LT promoter/CAT or the HTLV-I LTR/ CAT constructs was either cotransfected with 3 pg of pcTax or an irrelevant plasmid (pGEM4 or KS-M13+). All transfections were repeated at least three times with independent plasmid preparations. After transfection, cells were seeded at lo6 cells/mL culture medium in 25 cm2 culture flasks (Costar, Cambridge, MA). Cell cultures were maintained at 3 7 T , 5% C02 and harvested 48 hours after transfection. For some experiments, PMA (20 ng/mL) was added 24 hours before harvest. Cell extracts were prepared by freeze thawing and treatment at 65°C for 10 minutes. Reporter gene (CAT) activity was analyzed either according to the thin-layer chromatography (TLC) Cell transfection and CAT assays. methods described by Gorman et alZ9 or according to a liquid-phase acetylation method reported re~ently.~' In the latter case, samples were counted on a Beckman liquid scintillation counter at various time points up to 16 hours. In both assays, equal amounts of cellular protein were used as determined by the BioRad protein assay (BioRad, Richmond, CA).
RESULTS

Analysis of the human LT-promoter activity in HTLV-
I-infected cells. To determine regions within the 5' regulatory part of the LT gene required for promoter activity, a series of 5' deletion fragments was inserted upstream of the CAT reporter gene (psPCAT; Fig 1) . The activity of the different plasmid constructs was determined after transfection into MT-2 cells, which constitutively produce LT." Maximum promoter activity was observed with deletion constructs ranging from position -304 to -252 (Fig 2) . Smaller constructs showed a decrease in activity that was most pronounced with construct pLT-116. The addition of PMA to transfected MT-2 cells 24 hours before harvest led to an increase in the promoter activity (Fig 2) of all constructs.
Comparison of the 5' untranslated region of the humanz5 and mouse3' LT genes shows a greater than 90% sequence identity extending 220 nucleotides upstream of the start site of transcription of the human LT gene. promoter," we wanted to ascertain the relevance of this NF-KB binding site for the activation ofthe human LT promoter. For this purpose. we introduced a mutation into the critical region by PCR amplification (Fig 3A) . Transfection of the mutated LT/CAT plasmid (pLT-I 16mut) into MT-2 cells showed that the activity of the LT promoter (pLT-I 16) was completely lost after the substitution of three nucleotides within the KB sequence (Fig 38) . Stimulation of MT-2 cells with PMA could not restore wild-type promoter activity of the mutated plasmid (Fig 3B) .
E' ecr qj'tax and/or PMA on rhe LT-promoter acfivify in Jiirkat and U937 cells. Transfection of the pspCAT control plasmid into U937 and Jurkat cells yielded high background activity after stimulation with PMA. We therefore established a series of LT/CAT constructs using the pCAT3M plasmid24 as the basic vector (Fig IA and  C) . Transfection experiments showed that these plasmids were active in MT-2 cells, albeit to a lower extent than the LT/CAT constructs described above (data not shown). To test the effect of HTLV-I tax on the LT promoter, the LT/ CAT deletion constructs were cotransfected into Jurkat and U937 cells either together with a plasmid containing the HTLV-I faxgene under the control of a CMV promoter (pcTax)26 or an irrelevant plasmid.
As shown in Fig 4 A , cotransfection of LT/CAT constructs and pcTax resulted in the detection of promoter activity. The activity could be significantly increased by stimulation of the cells with PMA (Fig 4B) . In contrast, LT/CAT constructs cotransfected with irrelevant plasmid DNA were inactive in unstimulated (Fig 4A) Jurkat cells and stimulation with PMA led to a modest increase in CAT activity only with the construct LT-149 (Fig 4B) . Using a liquid-phase CAT assay,30 we could confirm. the data obtained with the TLC assay (Fig 5A) . In U937 cells, LT-promoter constructs were not active and cotransfection of pcTax induced promoter activity only after additional stimulation of these cells with PMA (Fig 5B) .
DISCUSSION
We have analyzed the human LT promoter using deletion constructs of the 5' untranslated region of the LT gene joined to a CAT reporter gene. These LT-promoter constructs were highly active when transfected into HTLV-I-infected MT-2 cells. Maximal activity was observed with constructs extending to positions -304 and -252 of the LT gene, but even deletions progressing as far as position -I 16 did not completely abrogate LT-promoter activity.
By mutation studies we could demonstrate that a single KB ~i t e "~. '~ present at positions -89 to -99 is crucial for the function of the human LT promoter because elimination of this site abolished promoter activity in unstimulated as well as PMA-stimulated MT-2 cells. This has been previously shown only for the murine LT gene." For transfection experiments involving HTLV-I-uninfected cell lines, a different set of LT-promoter constructs was used, as indicated in Results. These LT-promoter/CAT constructs showed no sig- Among the various biologic effects of LT, its antitumor7 and antivirallo*" activities are the most relevant clinically. The demonstration that HTLV-I tax is able to induce the LT promoter suggests that the activation of the LT gene in HTLV-I-infected cells" is not due to cellular defense mechanisms in response to viral infection, but rather is a direct or indirect effect of the HTLV-I regulatory gene product tax on the LT-promoter region. The activation of LT in HTLV-Iinfected cells suggests the participation of this lymphokine in the pathogenesis of HTLV-I-induced diseases. Hypercalcemia (with and without osteolytic bone lesions) is frequently observed in ATL patients." Several cytokines produced by HTLV-I-infected cells have been suggested in the past to contribute to these symptom^.^'.^^" LT activates osteoclasts," induces hypercalcemia in mice," and acts synergistically with other osteoclast-activating factors in bone resorption." It is therefore conceivable that induction of LT by HTLV-I in vivo contributes to the development of the osteolytic bone lesions and hypercalcemia frequently observed in ATL patients. This assumption is supported by data from a study by Ishibashi et al,' " who reported that Japanese ATL patients with hypercalcemia exhibit elevated serum levels of LT.
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